IP Library Granted Patent US 10,017,741
Granted Patent B2
US 10,017,741 · App. 14/776,866 · Granted Jul 10, 2018

Compositions and methods for obtaining enriched mesenchymal stem cell cultures

Inventors: Brenton John Short (Felixstow, AU); Christopher Duronio (Vancouver, CA)
Assignee: STEMCELL TECHNOLOGIES INC.
C12N5/0663C12N5/0668C12N2501/727C12N2501/999
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,017,741
App. No.
14/776,866
Granted
Jul 10, 2018
Kind
B2
Abstract

The disclosure provides a method of culturing cells of the mesenchymal cell lineage, said method comprising contacting the cells with a culture media comprising a CSF1R kinase inhibitor. The disclosure also provides a method of culturing cells from bone marrow and/or compact bone to enrich the cells with cells of the mesenchymal cell lineage comprising contacting the cells with a culture media comprising a CSF1R kinase inhibitor. Cell culture media comprising a CSF1R kinase inhibitor and useful for culturing cells of the mesenchymal cell lineage and/or enriching cells of the mesenchymal cell lineage is also provided.

Claims (11)

1. A method of increasing the number of mesenchymal cell in a sample comprising cells of the mesenchymal cell lineage and non-mesenchymal cells, said method comprising contacting the sample with a culture media comprising a Colony Stimulating Factor 1 Receptor (CSF1R) kinase inhibitor to increase the number of mesenchymal cells, wherein the method does not require removal of the non-mesenchymal cells prior to adding the CSF1R kinase inhibitor.

2. The method of claim 1 , wherein the method comprises:

a) harvesting cells from a tissue sample obtained from a subject, wherein the harvested cells comprise cells of the mesenchymal cell lineage and non-mesenchymal cells, and

b) contacting the harvested cells with a culture media comprising a CSF1R kinase inhibitor, and optionally

c) obtaining a population of cells enriched for cells of the mesenchymal cell lineage.

3. The method of claim 2 , wherein the tissue sample comprises bone marrow, compact bone or adipose tissue.

4. The method of claim 1 , wherein the CSF1R kinase inhibitor is GW2580, KI20227, HY-13075, cFMS Receptor Inhibitor II, cFMS Receptor Inhibitor III, cFMS Receptor Inhibitor IV or ARRY-382.

5. The method of claim 1 , wherein the cells of the mesenchymal cell lineage comprise at least one of a mesenchymal stem cell, a mesenchymal cell progenitor and a stromal-derived cell.

6. The method of claim 1 , wherein the cells are contacted with the culture media for at least one hour, at least one day or at least one week.

7. The method of claim 1 , wherein prior to contacting the cells with the culture media, the concentration of the cells of the mesenchymal cell lineage is at least 10 cells/cm 2 .

8. The method of claim 1 , wherein the cells of the mesenchymal cell lineage retain their ability to form adipogenic, chrondrogenic and osteogenic cell lineages.

Assignments (2)
SECURITY INTEREST Recorded Jun 30, 2022
From: STEMCELL TECHNOLOGIES CANADA INC.
To: HSBC BANK CANADA
Reel/Frame 060544/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2015
From: SHORT, BRENTON JOHN; DURONIO, CHRISTOPHER
To: STEMCELL TECHNOLOGIES INC.
Reel/Frame 037314/0346 →
Continuity (2)
Provisional Application 61789530 · Mar 15, 2013
Related Publication 20160032248A1 · Feb 4, 2016